Murine bone marrow stromal cells: implications for their use in gene modified cell therapy

Area of Science:

• Oncology
• Immunology
• Regenerative Medicine

Background:

• Hematologic diseases, such as lymphoma, represent a significant challenge in clinical therapy.
• Gene and cell therapies offer novel treatment strategies for hematologic malignancies.
• Bone marrow stromal cells (BMSC) are being explored as a platform for therapeutic gene delivery.

Purpose of the Study:

• To investigate the therapeutic potential of genetically modified bone marrow stromal cells (BMSC) in a murine lymphoma model.
• To evaluate the efficacy of BMSC engineered to express human interleukin-2 (hIL-2) for treating B-cell lymphoma.

Main Methods:

• Bone marrow stromal cells (BMSC) from Balb/c AnN mice were genetically modified using an adenoviral vector to express the human IL-2 gene (hIL-2).
• A murine B lymphoma (A20) cell line was injected intravenously into mice.
• Mice were subsequently divided into four treatment groups: control (no BMSC), unmodified BMSC, BMSC with Ad/deltaE1, and BMSC with Ad/hIL-2.
• Therapeutic effects were assessed over an 8-week observation period.

Main Results:

• All mice treated with BMSC engineered to express hIL-2 (BMSC (Ad/hIL-2)) survived the 8-week observation period with no evidence of disease.
• In contrast, control groups (no BMSC, unmodified BMSC, BMSC with Ad/deltaE1) showed disseminated lymphoma, with 80% mortality within 4 weeks.

Conclusions:

• Interleukin-2 (IL-2) gene-modified bone marrow stromal cells (BMSC) demonstrate significant therapeutic efficacy in a murine lymphoma model.
• This genetically modified BMSC approach represents a promising novel therapeutic tool for hematologic diseases like lymphoma.